Stock Price
31.61
Daily Change
0.21 0.67%
Monthly
-0.44%
Yearly
0.93%
Q2 Forecast
31.38

EPS Reference Time Actual Consensus Previous
2026-05-27 FY2026H2 0.13 0.38
2025-11-25 FY2026H1 AM 0.36 0.51 0.26
2025-05-27 FY2025H2 AM 0.38 0.34 0.04
2024-11-27 FY2025H1 0.26 0.18 0.18
2024-05-28 FY2024H2 0.04 0.24 0.27



Peers Price Chg Day Year Date
Cochlear 172.00 -3.06 -1.75% -33.67% Apr/15
CSL 139.44 1.36 0.98% -42.35% Apr/15
Nanosonics 3.55 -0.03 -0.84% -26.80% Apr/15
Ramsay Health Care 40.53 0.88 2.22% 23.98% Apr/15
ResMed 32.70 0.49 1.52% -1.03% Apr/15
Sonic Healthcare 20.46 0.37 1.84% -19.13% Apr/15
Somnomed 0.58 0.01 1.75% 31.82% Apr/14

Indexes Price Day Year Date
ASX200 8959 7.88 0.09% 15.47% Apr/15
ASX All Share 9181 16.00 0.17% 15.32% Apr/15

Fisher & Paykel Healthcare traded at 31.61 this Wednesday April 15th, increasing 0.21 or 0.67 percent since the previous trading session. Looking back, over the last four weeks, Fisher & Paykel Healthcare gained 0.44 percent. Over the last 12 months, its price rose by 0.93 percent. Looking ahead, we forecast Fisher & Paykel Healthcare to be priced at 31.38 by the end of this quarter and at 29.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The Company’s segment includes North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, and Other segment includes New Zealand, Latin America, Africa, the Middle East and other countries.